Supporting generally oncogenic roles, CBX2 and CBX8 have emerged as targets in lymphoma (190), hepatocellular carcinoma (201), breast cancer (202,203), prostate cancer (204) and ovarian cancer (205), while CBX6 and CBX7 have been implicated as tumor suppressors in thyroid cancer (206) lung cancer (207), glioblastoma (208), bladder cancer (209), cervical cancer (210) and breast cancer (211). Here, CBX2 is linked to prostate carcinoma.